Clinical trials are essential for developing new cancer treatments, but systemic biases often result in underrepresentation of certain groups. Minority populations, women, and those from lower socio-economic backgrounds are less likely to be included in clinical trials. This lack of diversity can skew the results and limit the applicability of new treatments to a broader population.
